Product Information
QC DUAL ACTION PAIN 250-125 MG is a generic product labeled by Chain Drug Marketing Association, priced at $0.1071 per EA under NDC 83324014936. Its NADAC has been published 96 times since Dec 4, 2024.
FDA first approved this application on Aug 1, 2023.
Strength
250; 125 mg/1; mg/1
Manufacturer
Chain Drug Marketing AssociationNDC
83324014936
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ACETAMINOPHEN; IBUPROFENApproval Type
Generic (ANDA)
FDA Application
ANDA216999FDA Approved
8/1/2023
On Market Since
10/3/2024
Pharmacological Classes
Price Statistics
The NADAC for QC DUAL ACTION PAIN 250-125 MG has been published 96 times since Dec 4, 2024, and over the history we have for it it has risen 27.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1071 per EA |
|---|---|
| All-time high | $0.1086 (Jul 16, 2025) |
| All-time low | $0.0839 (Apr 22, 2026) |
| 52-week high | $0.1071 |
| 52-week low | $0.0839 |
| Median price | $0.0907 |
| Average price | $0.0931 |
| Largest weekly change | +11.7% (May 21, 2025) |
| Weeks tracked | 96 |
| Tracking since | Dec 4, 2024 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 21% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Chain Drug Marketing Association manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Acetaminophen and Ibuprofen market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of QC DUAL ACTION PAIN 250-125 MG?
The current National Average Drug Acquisition Cost (NADAC) for QC DUAL ACTION PAIN 250-125 MG, manufactured by Chain Drug Marketing Association, is $0.1071 per EA (NDC 83324014936), effective Sep 30, 2026.
How has the price of QC DUAL ACTION PAIN 250-125 MG changed over time?
Over the history we have for it, the NADAC for QC DUAL ACTION PAIN 250-125 MG has risen 27.4%. It has been tracked across 96 weekly CMS publications since Dec 4, 2024.
What are the highest and lowest recorded NADAC prices for QC DUAL ACTION PAIN 250-125 MG?
Since Dec 4, 2024, the NADAC for QC DUAL ACTION PAIN 250-125 MG has ranged from a low of $0.0839 (Apr 22, 2026) to a high of $0.1086 (Jul 16, 2025), with a median of $0.0907 per EA.
Are there cheaper alternatives to QC DUAL ACTION PAIN 250-125 MG?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ACETAMINOPHEN-IBUPROFEN 250-125 MG CAPLET, is $0.0844 per EA — about 21% below QC DUAL ACTION PAIN 250-125 MG.
Who manufactures QC DUAL ACTION PAIN 250-125 MG?
QC DUAL ACTION PAIN 250-125 MG (NDC 83324014936) is labeled by Chain Drug Marketing Association, and CMS classifies it as a generic product.